ArticleEvolution, medicine, and public health2026
Lessons from oncology: Can cancer lead the way in resistance management?
Article in Evolution, medicine, and public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The evolution of resistance to chemical interventions is a widespread challenge in medicine and agriculture, affecting bacteria, viruses, parasites, cancer, pests, and weeds. Many resistance management strategies have been proposed, but empirical comparisons are rare, especially in large-scale systems like agriculture and public health, where populations are difficult to replicate, and interventions cannot easily be tested experimentally. Cancer offers a unique opportunity to study resistance evolution. Because evolution occurs within individual patients, resistance strategies can be tested directly in clinical trials, with each patient serving as an independent replicate. Combined with diverse therapies and experimental models, this makes oncology a powerful system for studying therapeutic resistance. Whether insights from cancer apply to other systems remains an open but testable question. Addressing this could reveal general principles of resistance evolution and help unify currently fragmented approaches to resistance management across disciplines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.